ReqMed Company, Ltd.

Based in Japan, ReqMed Company, Ltd. specializes in developing and commercializing pharmaceuticals aimed at addressing unmet medical needs, focusing on innovative therapeutic solutions for diverse patient populations. Founded in 1998 in Tokyo, Japan, ReqMed Company, Ltd. is engaged in the pharmaceutical sector, offering products that cater to specific medicinal needs.

The company has successfully completed 3 funding deals, with the most recent occurring on June 16, 2025, when it raised JPY 1. 3 billion from investor FUNDINNO. This funding will support the clinical testing and development of a drug targeting osteoarthritis of the knee. ReqMed Company, Ltd.

specializes in the development and commercialization of pharmaceuticals that address unmet medical needs. Their core product offerings include innovative drugs designed to cater to patients requiring specific medicinal solutions, emphasizing their commitment to the philosophy of “Required Medicine for all who request it. ” These products are intended to improve patient outcomes across various medical conditions, particularly those that are not adequately addressed by existing treatments. The company primarily focuses on markets in Japan and aims to expand its influence in other regions, continually striving to provide effective therapeutic options for healthcare professionals and patients alike.

By closely aligning their product development with patient needs, ReqMed serves a diverse customer base, including healthcare providers, pharmacies, and hospitals. The revenue model for ReqMed Company, Ltd. is structured around direct sales of pharmaceuticals to healthcare providers, alongside potential partnerships with medical institutions for research and development initiatives. The firm engages in B2B transactions, supplying hospitals and clinics with their flagship products, which are positioned to meet specific healthcare demands.

The revenue generation may also involve collaborations with wholesalers for broader distribution channels. While the exact pricing plans for their products are not detailed, the company’s focus on ensuring accessibility to their medicines aligns with their mission to cater to all who require them. This transaction structure reflects a commitment to creating a sustainable business model that prioritizes patient needs while supporting healthcare professionals in their practice. In June 2025, ReqMed Company, Ltd.

raised JPY 1. 3 billion in venture funding from new investor FUNDINNO. The funding will be utilized for the clinical test and development of its drug to treat osteoarthritis of the knee. The company is also actively exploring opportunities to expand into new markets beyond Japan, although specific regions have not yet been detailed.